BACKGROUND: The discovery of potent and broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus (HIV) has made passive immunization a potential strategy for the prevention and treatment of HIV infection. We sought to determine whether passive administration of VRC01, a bNAb targeting the HIV CD4-binding site, can safely prevent or delay plasma viral rebound after the discontinuation of antiretroviral therapy (ART). METHODS: We conducted two open-label trials (AIDS Clinical Trials Group [ACTG] A5340 and National Institutes of Health [NIH] 15-I-0140) of the safety, side-effect profile, pharmacokinetic properties, and antiviral activity of VRC01 in persons with HIV infection who were undergoing interruption of ART. RESULTS: A total of 24 participants were enrolled, and one serious alcohol-related adverse event occurred. Viral rebound occurred despite plasma VRC01 concentrations greater than 50 μg per milliliter. The median time to rebound was 4 weeks in the A5340 trial and 5.6 weeks in the NIH trial. Study participants were more likely than historical controls to have viral suppression at week 4 (38% vs. 13%, P=0.04 by a two-sided Fisher's exact test in the A5340 trial; and 80% vs. 13%, P<0.001 by a two-sided Fisher's exact test in the NIH trial) but the difference was not significant at week 8. Analyses of virus populations before ART as well as before and after ART interruption showed that VRC01 exerted pressure on rebounding virus, resulting in restriction of recrudescent viruses and selection for preexisting and emerging antibody neutralization-resistant virus. CONCLUSIONS: VRC01 slightly delayed plasma viral rebound in the trial participants, as compared with historical controls, but it did not maintain viral suppression by week 8. In the small number of participants enrolled in these trials, no safety concerns were identified with passive immunization with a single bNAb (VRC01). (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTG A5340 and NIH 15-I-0140 ClinicalTrials.gov numbers, NCT02463227 and NCT02471326 .).
BACKGROUND: The discovery of potent and broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus (HIV) has made passive immunization a potential strategy for the prevention and treatment of HIV infection. We sought to determine whether passive administration of VRC01, a bNAb targeting the HIVCD4-binding site, can safely prevent or delay plasma viral rebound after the discontinuation of antiretroviral therapy (ART). METHODS: We conducted two open-label trials (AIDS Clinical Trials Group [ACTG] A5340 and National Institutes of Health [NIH] 15-I-0140) of the safety, side-effect profile, pharmacokinetic properties, and antiviral activity of VRC01 in persons with HIV infection who were undergoing interruption of ART. RESULTS: A total of 24 participants were enrolled, and one serious alcohol-related adverse event occurred. Viral rebound occurred despite plasma VRC01 concentrations greater than 50 μg per milliliter. The median time to rebound was 4 weeks in the A5340 trial and 5.6 weeks in the NIH trial. Study participants were more likely than historical controls to have viral suppression at week 4 (38% vs. 13%, P=0.04 by a two-sided Fisher's exact test in the A5340 trial; and 80% vs. 13%, P<0.001 by a two-sided Fisher's exact test in the NIH trial) but the difference was not significant at week 8. Analyses of virus populations before ART as well as before and after ART interruption showed that VRC01 exerted pressure on rebounding virus, resulting in restriction of recrudescent viruses and selection for preexisting and emerging antibody neutralization-resistant virus. CONCLUSIONS:VRC01 slightly delayed plasma viral rebound in the trial participants, as compared with historical controls, but it did not maintain viral suppression by week 8. In the small number of participants enrolled in these trials, no safety concerns were identified with passive immunization with a single bNAb (VRC01). (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTG A5340 and NIH 15-I-0140 ClinicalTrials.gov numbers, NCT02463227 and NCT02471326 .).
Authors: Elin S Gray; Maphuti C Madiga; Penny L Moore; Koleka Mlisana; Salim S Abdool Karim; James M Binley; George M Shaw; John R Mascola; Lynn Morris Journal: J Virol Date: 2009-08-19 Impact factor: 5.103
Authors: Meghan K Rothenberger; Brandon F Keele; Stephen W Wietgrefe; Courtney V Fletcher; Gregory J Beilman; Jeffrey G Chipman; Alexander Khoruts; Jacob D Estes; Jodi Anderson; Samuel P Callisto; Thomas E Schmidt; Ann Thorkelson; Cavan Reilly; Katherine Perkey; Thomas G Reimann; Netanya S Utay; Krystelle Nganou Makamdop; Mario Stevenson; Daniel C Douek; Ashley T Haase; Timothy W Schacker Journal: Proc Natl Acad Sci U S A Date: 2015-02-23 Impact factor: 11.205
Authors: Tae-Wook Chun; Danielle Murray; Jesse S Justement; Jana Blazkova; Claire W Hallahan; Olivia Fankuchen; Kathleen Gittens; Erika Benko; Colin Kovacs; Susan Moir; Anthony S Fauci Journal: Proc Natl Acad Sci U S A Date: 2014-08-25 Impact factor: 11.205
Authors: T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci Journal: Proc Natl Acad Sci U S A Date: 1997-11-25 Impact factor: 11.205
Authors: Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola Journal: Science Date: 2010-07-08 Impact factor: 47.728
Authors: Amarendra Pegu; Zhi-yong Yang; Jeffrey C Boyington; Lan Wu; Sung-Youl Ko; Stephen D Schmidt; Krisha McKee; Wing-Pui Kong; Wei Shi; Xuejun Chen; John-Paul Todd; Norman L Letvin; Jinghe Huang; Martha C Nason; James A Hoxie; Peter D Kwong; Mark Connors; Srinivas S Rao; John R Mascola; Gary J Nabel Journal: Sci Transl Med Date: 2014-07-02 Impact factor: 17.956
Authors: Rebecca M Lynch; Lillian Tran; Mark K Louder; Stephen D Schmidt; Myron Cohen; Rebecca Dersimonian; Zelda Euler; Elin S Gray; Salim Abdool Karim; Jennifer Kirchherr; David C Montefiori; Sengeziwe Sibeko; Kelly Soderberg; Georgia Tomaras; Zhi-Yong Yang; Gary J Nabel; Hanneke Schuitemaker; Lynn Morris; Barton F Haynes; John R Mascola Journal: J Virol Date: 2012-05-09 Impact factor: 5.103
Authors: Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton Journal: Nature Date: 2013-10-30 Impact factor: 49.962
Authors: Anne-Sophie Kuhlmann; Kevin G Haworth; Isaac M Barber-Axthelm; Christina Ironside; Morgan A Giese; Christopher W Peterson; Hans-Peter Kiem Journal: Mol Ther Date: 2018-09-27 Impact factor: 11.454
Authors: Rebecca T Veenhuis; Zachary T Freeman; Jack Korleski; Laura K Cohen; Guido Massaccesi; Alessandra Tomasi; Austin W Boesch; Margaret E Ackerman; Joseph B Margolick; Joel N Blankson; Michael A Chattergoon; Andrea L Cox Journal: J Clin Invest Date: 2017-10-30 Impact factor: 14.808
Authors: José M Martinez-Navio; Sebastian P Fuchs; Shara N Pantry; William A Lauer; Natasha N Duggan; Brandon F Keele; Eva G Rakasz; Guangping Gao; Jeffrey D Lifson; Ronald C Desrosiers Journal: Immunity Date: 2019-03-05 Impact factor: 31.745
Authors: Wen Shi Lee; Anne B Kristensen; Thomas A Rasmussen; Martin Tolstrup; Lars Østergaard; Ole S Søgaard; Bruce D Wines; P Mark Hogarth; Arnold Reynaldi; Miles P Davenport; Sean Emery; Janaki Amin; David A Cooper; Virginia L Kan; Julie Fox; Henning Gruell; Matthew S Parsons; Stephen J Kent Journal: J Virol Date: 2017-07-12 Impact factor: 5.103
Authors: D Brenda Salantes; Yu Zheng; Felicity Mampe; Tuhina Srivastava; Subul Beg; Jun Lai; Jonathan Z Li; Randall L Tressler; Richard A Koup; James Hoxie; Mohamed Abdel-Mohsen; Scott Sherrill-Mix; Kevin McCormick; E Turner Overton; Frederic D Bushman; Gerald H Learn; Robert F Siliciano; Janet M Siliciano; Pablo Tebas; Katharine J Bar Journal: J Clin Invest Date: 2018-06-18 Impact factor: 14.808
Authors: Justin Harper; Shari Gordon; Chi Ngai Chan; Hong Wang; Emily Lindemuth; Cristin Galardi; Shane D Falcinelli; Samuel L M Raines; Jenna L Read; Kevin Nguyen; Colleen S McGary; Michael Nekorchuk; Kathleen Busman-Sahay; James Schawalder; Colin King; Maria Pino; Luca Micci; Barbara Cervasi; Sherrie Jean; Andrew Sanderson; Brian Johns; A Alicia Koblansky; Heather Amrine-Madsen; Jeffrey Lifson; David M Margolis; Guido Silvestri; Katharine J Bar; David Favre; Jacob D Estes; Mirko Paiardini Journal: Nat Med Date: 2020-03-16 Impact factor: 53.440